Literature DB >> 15639784

Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD.

Nihar Ranjan Jana1, Nobuyuki Nukina.   

Abstract

A major hallmark of the polyglutamine diseases is the formation of neuronal intranuclear inclusions (NIIs) of the disease proteins that are ubiquitinated and often associated with various chaperones and proteasome components. Recently, misfolding has come to be considered one of the primary factors for polyglutamine protein aggregation, although, the nature of misfolding and the relationship between misfolding and ubiquitination of the expanded polyglutamine protein is not yet known. By using ataxin-3, the defective gene product of SCA3/MJD, we demonstrate here that the misfolding propensity and the cellular toxicity of a polyglutamine protein is directly proportional to the length of the glutamine repeats and inversely dependent on the size of the corresponding protein. The size of the polyglutamine bearing protein also inversely influences the binding of 1C2 antibody (an antibody that selectively recognizes polyglutamine expansion) to the polyglutamine protein and determines the minimum length of glutamine expansion to be recognized by 1C2 antibody, which suggests that the critical pathological range of glutamine repeats could also be dependent on the size of the corresponding protein. Ataxin-3 (both full length and truncated) with normal glutamine repeats are not ubiquitinated, however, ataxin-3 with expanded polyglutamine is ubiquitinated and the ubiquitination depends on the misfolding propensity of the polyglutamine expanded ataxin-3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15639784     DOI: 10.1007/BF03033448

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  43 in total

1.  Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity.

Authors:  L M Ellerby; A S Hackam; S S Propp; H M Ellerby; S Rabizadeh; N R Cashman; M A Trifiro; L Pinsky; C L Wellington; G S Salvesen; M R Hayden; D E Bredesen
Journal:  J Neurochem       Date:  1999-01       Impact factor: 5.372

Review 2.  Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold.

Authors:  H L Paulson
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

4.  Machado-Joseph disease gene product identified in lymphocytes and brain.

Authors:  G Wang; K Ide; N Nukina; J Goto; Y Ichikawa; K Uchida; T Sakamoto; I Kanazawa
Journal:  Biochem Biophys Res Commun       Date:  1997-04-17       Impact factor: 3.575

5.  Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone.

Authors:  D L Stenoien; C J Cummings; H P Adams; M G Mancini; K Patel; G N DeMartino; M Marcelli; N L Weigel; M A Mancini
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

Review 6.  Glutamine repeats and neurodegeneration.

Authors:  H Y Zoghbi; H T Orr
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

Review 7.  Machado-Joseph disease: an autosomal dominant motor system degeneration.

Authors:  R N Rosenberg
Journal:  Mov Disord       Date:  1992       Impact factor: 10.338

8.  Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.

Authors:  N R Jana; M Tanaka; G h Wang; N Nukina
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

9.  Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.

Authors:  N R Jana; E A Zemskov; N Nukina
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

10.  Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.

Authors:  C J Cummings; M A Mancini; B Antalffy; D B DeFranco; H T Orr; H Y Zoghbi
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

View more
  6 in total

Review 1.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

Review 2.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

3.  Paradigm for disease deconvolution in rare neurodegenerative disorders in Indian population: insights from studies in cerebellar ataxias.

Authors:  Renu Kumari; Deepak Kumar; Samir K Brahmachari; Achal K Srivastava; Mohammed Faruq; Mitali Mukerji
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 4.  Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.

Authors:  Melvin M Evers; Lodewijk J A Toonen; Willeke M C van Roon-Mom
Journal:  Mol Neurobiol       Date:  2013-11-29       Impact factor: 5.590

5.  The Truncated C-terminal Fragment of Mutant ATXN3 Disrupts Mitochondria Dynamics in Spinocerebellar Ataxia Type 3 Models.

Authors:  Jung-Yu Hsu; Yu-Ling Jhang; Pei-Hsun Cheng; Yu-Fan Chang; Su-Han Mao; Han-In Yang; Chia-Wei Lin; Chuan-Mu Chen; Shang-Hsun Yang
Journal:  Front Mol Neurosci       Date:  2017-06-20       Impact factor: 5.639

6.  Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.

Authors:  Xin Tong; Dandan Xu; Rama K Mishra; Ryan D Jones; Leyu Sun; Gary E Schiltz; Jie Liao; Guang-Yu Yang
Journal:  J Biol Chem       Date:  2020-11-21       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.